Cost‐effectiveness analysis comparing advanced hybrid closed‐loop automated insulin delivery with multiple daily insulin injections and continuous glucose monitoring in adults with type 1 diabetes in Japan
5 affiliations
- 1Department of Diabetology, Endocrinology, and Metabolism National Center for Global Health and Medicine, Japan Institute for Health Security Tokyo Japan
- 2Medtronic International Trading Sàrl Tolochenaz Switzerland
- 3Okayama Saiseikai General Hospital Okayama Japan
- 4Covalence Research Ltd Harpenden UK
- 5Division of Diabetes and Endocrinology, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe City Japan
Abstract
Aim: The use of automated insulin delivery systems, including the MiniMed™ 780G advanced hybrid closed‐loop system, has been shown to improve glycemic management in people with type 1 diabetes (T1D). The aim was to assess the cost‐effectiveness of the MiniMed 780G system versus multiple daily injections (MDI) of insulin in combination with continuous glucose monitoring (CGM) in the management of people with T1D with elevated HbA1c levels in Japan.
Methods: Modeling was performed using the IQVIA Core Diabetes Model and clinical input data were sourced from a randomized controlled trial. A time horizon of 55 years, a discount rate of 2.0% per annum, and a payer perspective were used. Sensitivity analyses were used to examine the robustness of base‐case results.
Results: In the base‐case, an incremental cost‐effectiveness ratio (ICER) of JPY 4,723,991 per quality‐adjusted life year (QALY) gained was found, with an incremental benefit of 2.83 quality‐adjusted life years with the MiniMed 780G system versus MDI + CGM. The MiniMed 780G system was therefore cost‐effective, assuming a willingness‐to‐pay threshold of JPY 5,000,000 per QALY. Although treatment costs were found to be JPY 16,226,167 higher for the MiniMed 780G, costs associated with managing long‐term complications were lower. A probabilistic sensitivity analysis found the intervention to have a 76.9% probability of being cost‐effective in Japan.
Conclusion: The MiniMed 780G system was projected to be cost‐effective in the management of people with T1D in Japan with HbA1c above target levels. Its use was also predicted to improve clinical outcomes when compared with MDI + CGM.
Related
- Continuous glucose monitoring, automated insulin delivery, and remote care in adolescents with type 1 diabetes: advances toward integrated digital management
- An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults
- Comparing Effectiveness of Antidepressants for Nursing Home Residents with Dementias and Depressive Symptoms
- TeleBACK clinical trial: comparing the effectiveness of telerehabilitation and in-clinic physical therapy for patients with chronic low back pain - protocol for a multicentre, pragmatic, individually randomised group treatment trial.
- Comparing the effectiveness of emotion-focused therapy and cognitive rehabilitation based on RehaCom software on emotional and cognitive components in female migraine patients: A randomized control trial.
BibTeX
@article{kodani2026costeffectiveness,
title = {{Cost‐effectiveness analysis comparing advanced hybrid closed‐loop automated insulin delivery with multiple daily insulin injections and continuous glucose monitoring in adults with type 1 diabetes in Japan}},
author = {Noriko Kodani and Aslı Zeynep Ozdemir Saltik and Atsuhito Tone and Martin Field and Richard F. Pollock and Michelle Hill and Yushi Hirota and Simona de Portu},
journal = {Journal of diabetes investigation},
year = {2026},
month = oct,
doi = {10.1111/jdi.70459},
url = {https://europepmc.org/article/PMC/PMC13722974},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Cost‐effectiveness analysis comparing advanced hybrid closed‐loop automated insulin delivery with multiple daily insulin injections and continuous glucose monitoring in adults with type 1 diabetes in Japan
AU - Noriko Kodani
AU - Aslı Zeynep Ozdemir Saltik
AU - Atsuhito Tone
AU - Martin Field
AU - Richard F. Pollock
AU - Michelle Hill
AU - Yushi Hirota
AU - Simona de Portu
PY - 2026
DA - 2026/10/31
JO - Journal of diabetes investigation
DO - 10.1111/jdi.70459
UR - https://europepmc.org/article/PMC/PMC13722974
AB - Aim: The use of automated insulin delivery systems, including the MiniMed™ 780G advanced hybrid closed‐loop system, has been shown to improve glycemic management in people with type 1 diabetes (T1D). The aim was to assess the cost‐effectiveness of the MiniMed 780G system versus multiple daily injections (MDI) of insulin in combination with continuous glucose monitoring (CGM) in the management of people with T1D with elevated HbA1c levels in Japan. Methods: Modeling was performed using the IQVIA Core Diabetes Model and clinical input data were sourced from a randomized controlled trial. A time horizon of 55 years, a discount rate of 2.0% per annum, and a payer perspective were used. Sensitivity analyses were used to examine the robustness of base‐case results. Results: In the base‐case, an incremental cost‐effectiveness ratio (ICER) of JPY 4,723,991 per quality‐adjusted life year (QALY) gained was found, with an incremental benefit of 2.83 quality‐adjusted life years with the MiniMed 780G system versus MDI + CGM. The MiniMed 780G system was therefore cost‐effective, assuming a willingness‐to‐pay threshold of JPY 5,000,000 per QALY. Although treatment costs were found to be JPY 16,226,167 higher for the MiniMed 780G, costs associated with managing long‐term complications were lower. A probabilistic sensitivity analysis found the intervention to have a 76.9% probability of being cost‐effective in Japan. Conclusion: The MiniMed 780G system was projected to be cost‐effective in the management of people with T1D in Japan with HbA1c above target levels. Its use was also predicted to improve clinical outcomes when compared with MDI + CGM.
SN - 2040-1116
SN - 2040-1124
ER -